KACTUS, a leading recombinant protein manufacturer, has published a technical framework for engineering 2+1 and trispecific T-cell engager (TCE) therapeutics.

In this issue of JCO Oncology Practice, Majhail et al 1 describe their organization's experience with outpatient chimeric antigen receptor T-cell (CAR-T) cell therapy using a remote patient monitoring ...

Chimeric antigen receptor T-cell therapy (CAR T) has revolutionized oncology treatment over the last decade, offering targeted therapy options for several difficult cancers, espec ...

Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...